Presence of circulating CTL induced by infection with wild-type or attenuated SIV and their correlation with protection from pathogenic SHIV challenge

Journal of Medical Primatology

Volumn 27, Issue 2-3, 1998, Pages 65-72

  Vogel, Thorsten U ^a   Fournier, Jocelyn ^b   Sheering, Alice ^a   Ko, Doreen ^a   Parenteau, Monique ^b   Bogdanovic, Dragica ^a   Mihowich, Jennifer ^a   Rud, Erling W ^a,b  

^a LAB CENTRE FOR DISEASE CONTROL   (Canada)

^b HEALTH CANADA   (Canada)

Author keywords

AIDS vaccine; CTL precursor frequency; Cynomolgus macaques; Cytotoxic T Lymphocytes; Non Human primates

Indexed keywords

ANIMALIA; MACACA; PRIMATES; SIMIAN IMMUNODEFICIENCY VIRUS; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RECOMBINANT VACCINE; VIRUS VACCINE;

ANIMAL; ARTICLE; B LYMPHOCYTE; CELL LINE; CYTOTOXIC T LYMPHOCYTE; GENETIC REASSORTMENT; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MACACA; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINIA VIRUS; VIROLOGY;

AIDS VACCINES; ANIMALS; B-LYMPHOCYTES; CELL LINE; HIV; LYMPHOCYTE ACTIVATION; MACACA FASCICULARIS; MACACA MULATTA; REASSORTANT VIRUSES; SIMIAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRAL VACCINES;

EID: 0032038760     PISSN: 00472565     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0684.1998.tb00228.x     Document Type: Article

References (38)

1. ABIMIKU AG, FRANCHINI G, ALDRICH K, MYAGKIKH M, MARKHAM P, GARD E, GALLO RC, ROBERT-GUROFF M: Humoral and cellular immune responses in rhesus macaques infected with human immunodeficiency virus type 2, AIDS Res Hum Retroviruses 11:383-393, 1995.
2. ADA GL, MCELRATH MJ: HIV type 1 vaccine-induced cytotoxic T cell response: Potential role in vaccine efficacy. AIDS Res Hum Retrovinises 13:205-209, 1997.
3. ALMOND N, KENT K, CRANAGE M, RUD E, CLARKE B, STOTT EJ: Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. Lancet 345:1342-1344, 1995
4. BORROW P, LEWICKI H, HAHN BH, SHAW GM, OLDSTONE MBA: Virus-specific CD8+ cytotoxic T-Lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 68:6103-6110, 1994.
5. BOURGAULT I, VILLEFROY P, BEYER C, AUBERTIN AM, LEVY JP, VENET A: Cytotoxic T-cell response and AIDS-free survival in simian immunodeficiency virus-infected macaques. AIDS 7:S73-S79, 1993.
6. BUSEYNE F, RIVIERE Y: HIV-specific CD8+ T-cell immune responses and viral replication. AIDS 7:S81-S85, 1993.
7. COUEDEL-COURTEILLE A, LE GRAND R, TULLIEZ M, GUILLET JG, VENET A: Direct ex vivo simian immunodeficiency virus (SIV)-specific cytotoxic activity detected from small intestine intraepithelial lymphocytes of SIV-infected macaques at an advanced stage of infection. J Virol 71:1052-1057, 1997.
8. DANIEL MD, KIRCHHOFF F, CZAJAK SC, SEHGAL PK, DESROSIERS RC: Protective effects of a live attentuated SIV vaccine with a deletion in the nef gene. Science 258:1938-1941, 1992.
9. DITTMER U, NISSLEIN T, BODEMER W, PETRY H, SAUERMANN U, STAHL-HENNIG C, HUNSMANN G: Cellular immune response of rhesus monkeys infected with a partially attenuated nef deletion mutant of the simian immunodeficiency virus. Virology 212:392-397, 1995.
10. DONNENBERG AD, MARGOLICK JB, POLK BF: Limiting dilution analysis of in vivo-activated (IL-2 responsive) peripheral blood lymphocytes in HIV-1-infected subjects. Clin Immunol Immunopathol 51:91-98, 1989.
11. FUJIMOTO K, TERATO K, MIYAMATO J, ISHIKO H, FUJISAKI M, CHO F, HONJO S: Establishment of a B-lymphoblastoid cell line infected with Epstein-Barr-related virus from a cynomolgus monkey (Macaca fascicularis). J Med Primatol 19:21-30, 1990.
12. GALLIMORE A, CRANAGE M, COOK N, ALMOND N, BOOTMAN J, RUD E, SILVERA P, DENNIS M, CORCORAN T, STOTT J, MCMICHAEL A, GOTCH F: Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques. Nat Med 1:1167-1173, 1995.
13. GERETTI AM, HULSKOTTE EGJ, DINGS MEM, VAN BAALEN CA, VAN AMERONGEN G, OSTERHAUS ADME: Simian immunodeficiency virus (SIV)-specific CD8+ cytotoxic T lymphocyte responses of naive and vaccinated cynomolgus macaques infected with SIVmac32H (J5): Quantitative analysis by in vitro antigenic stimulation. Vaccine 15:1269-1275, 1997.
14. GOTCH F, NIXON D, GALLIMORE A, MCADAM S, MCMICHAEL A: Cytotoxic T lymphocyte epitopes shared between HIV-1, HIV-2, and SIV. J Med Primatol 22:119-123, 1993.
15. GREENOUGH TC, BRETTLER BD, SOMASUNDARAN M, PANICALI DL, SULLIVAN JL: Human immunodeficiency virus type I-specific cytotoxic T lymphocytes (CTL), virus load, and CD4 T cell loss: Evidence supporting a protective role for CTL in vivo. J Infect Dis 176:118-125, 1997.
16. HARRER T, HARRER E, KALAMS SA, ELBEIK T, STAPRANS SI, FEINBERG MB, CAO Y, HO DD, YILMA T, CALIENDO AM, JOHNSON RP, BUCHBINDER SP, WALKER BD: Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. AIDS Res Hum Retroviruses 12:585-592, 1996.
17. KASLOW RA, CARRINGTON M, APPLE R, PARK L, MUNOZ A, SAAH AJ, GOEDERT JJ, WINKLER C, O'BRIEN SJ, RINALDO C, DETELS R, BLATTNER W, PHAIR J, ERLICH H, MANN DL: Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 2:405-411, 1996.
18. KLEIN MR, VAN BAALEN CA, HOLWERDA AM, KERKHOF GARDE SR, BENDE RJ, KEET IP, EEFTINCK-SCHATTENKERK JK, OSTERHAUS AD, SCHUITEMAKER H, MIEDEMA F: Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med 181:1365-1372, 1995.
19. KOUP RA, SAFRIT JT, CAO Y, ANDREWS CA, MCLEOD G, BORKOWSKY W, FARTHING C, Ho DD: Temporal association of cellular immune responses with the initial contorl of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 68:4650-4665, 1994.
20. LOHMAN BL, MCCHESNEY MB, MILLER CJ, MCGOWAN E, JOYE SM, VAN ROMPAY KK, REAY E, ANTIPA L, PEDERSEN NC, MARTHAS ML: A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge. J Virol 68:7021-7029, 1994.
21. LOHMAN BL, MCCHESNEY MB, MILLER CJ, OTSYULA M, BERARDI CJ, MARTHAS ML: Mucosal immunization with a live, virulence-attenuated simian immunodeficiency virus (SIV) vaccine elicits antiviral cytotoxic T lymphocytes and antibodies in rhesus macaques. J Med Primatol 23:95-101, 1994.
22. MCNEIL AJ, YAP PL, GORE SM, BRETTLE RP, MCCOLL M, WYLD R, DAVIDSON S, WEIGHTMAN R, RICHARDSON AM, ROBERTSON JR: Association of HLA types A1-B8-DR3 and B27 with rapid and slow progression of HIV disease. QJM 89:177-185, 1996.
23. MURPHEY CORB M: Live-attenuated HIV vaccines: How safe is safe enough? Nat Med 3:17-18, 1997.
24. NORLEY S, BEER B, BINNINGER SD, COSMA C, KURTH R: Protection from pathogenic SIVmac challenge following short-term infection with a nef-deficient attenuated virus. Virology 219:195-205, 1996.
25. PUTKONEN P, MAKITALO B, BOTTIGER D, BIBERFELD G, THORSTENSSON R: Protection of human immunodeficiency virus type 2-exposed seronegative macaques from mucosal simian immunodeficiency virus transmission. J Virol 71:4981-4984, 1997.
26. REIMANN KA, LI JT, VEAZEY R, HALLORAN M, PARK IW, KARLSSON GB, SODROSKI J, LETVIN NL: A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J Virol 70:6922-6928, 1996.
27. RINALDO C, HUANG XL, FAN ZF, DING M, BELTZ L, LOGAR A, PANICALI D, MAZZARA G, LIEBMANN J, COTTRILL M, GUPTA P: High level sof anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term non-progressors. J Virol 69:5838-5842, 1995.
28. RIVIERE Y, MCCHESNEY MB, PORROT F, TANNEAU-SALVADORI F, SANSONETTI P, LOPEZ O, PIALOUX G, FEUILLIE V, MOLLEREAU M, CHAMARET S, TEKAIA F, MONTAGNIER L: Gag-specific cytotoxic responses to HIV type 1 are associated with a decreased risk of progression to AIDS-related complex or AIDS. AIDS Res Hum Retroviruses 11:903-907, 1995.
29. ROUSE BT, NORLEY S, MARTIN S: Antiviral cytotoxic T lymphocyte induction and vaccination. Rev Infect Dis 10:16-33, 1988.
30. RUD EW, CRANAGE M, YON J, QUIRK J, OGILVIE L, COOK N, WEBSTER S, DENNIS M, CLARKE BE: Molecular and biological characterization of simian immunodeficiency virus macaque strain 32H proviral clones containing nef size variants. J Gen Virol 75:529-543, 1994.
31. RUD EW, OGILVIE L, CLARKE BE, ALMOND N, KENT K, CHAN L, PAGE M, KITCHIN P, STOTT J, COOK N, SHARPE S, ASHWORTH T, DENNIS M, HALL G, CRANAGE MP: A naturally attenuated SIVmac32H vaccine or viral interference? In: Vaccines 94. E. Norrby and F. Brown and R.M. Chanock and H.S. Ginsberg (eds). Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp 217-223, 1994.
32. RUD EW, VOGEL TU, SHERRING A, BROWN J, KO D, BOGDANOVIC D, KIM J, PARENTEAU M, BEAUSOLEIL N, REIMANN KA, LETVEN NL, CRANAGE MP, FOURNIER J: Infection with the anenutated SIVmacC8 does not completely protect against superinfection with SHIV89.6P, but provides protection against acute disease. Submitted 1998.
33. RUD EW, YON JR, LARDER BA, CLARKE BE, COOK N, CRANAGE MP: Infectious molecular clones of SIVmac32H: Nef deletion controls ability to reisolate virus from rhesus macaques. In: Vaccines 92. F. Brown and R.M. Chanock and H.S. Ginsberg and R. A. Lerner (eds). Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp 229-235, 1992.
34. RUPRECHT RM, BABA TW, LISKA V: Attentuated HIV vaccine: Caveats. Science 271:1790-1792, 1996.
35. VENET A, BOURGAULT I, AUBERTIN AM, KIENY MP, LEVY JP: Cytotoxic T lymphocyte response against multiple simian immunodeficiency virus A (SIV) proteins in SIV-infected macaques. J Immunol 148:2899-2908, 1992.
36. VOGEL TU, FOURNIER J, SHERRING A, PARENTEAU M, BEAUSOLEIL N, BROWN J, KO D, BOGDANOVIC D, RUD EW: Differences in virological and immunological parameters in cynomolgus macaques infected with the wild type SIVmacJ5 or the attenuated SIVmacC8. Submitted, 1998.
37. WYAND MS, MANSON K, DESROSIERS RC: Vaccine protection against pathogenic SIVmac251 using live-attenuated vaccines SIV239Δ3 and SIV316 Δnef. In: Conference on advances in AIDS vaccine development. Reston, USA, p 109, 1994.
38. XU XN, SCREATON GR, GOTCH FM, DONG T, TAN R, ALMOND N, WALKER B, STEBBINGS R, KENT K, NAGATA S, STOTT JE, MCMICHAEL AJ: Evasion of cytotoxic T lymphocyte (CTL) responses by nef-dependent induction of Fas ligand (CD95L) expression on simian immunodeficiency virus-infected cells. J Exp Med 186:7-16, 1997.